Alpha Teknova Inc. (TKNO)
NASDAQ: TKNOHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TKNO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $479.95M
- EPS (TTM)
- -$0.30
- Dividend yield
- None
- 52-week range
- 1.91 – 9.48
- Day range
- 7.52 – 7.80
- Volume / Avg
- 254.65K / 437.31K
- Beta
- —
- Shares outstanding
- 62.90M
52-week range
TKNO stock today
Shares of Alpha Teknova (TKNO) finished lower on Nov 20 at $7.63, a drop of 2.30% or $0.18 per share, versus the S&P 500's 3.70% decline. At this level, TKNO sits in the middle of its 52-week range of $1.91 to $9.48: 19.5% below the high, set on Sep 25, 2026 and 299.5% above the low. TKNO is up 100.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 77.4%.
Alpha Teknova has posted a net loss over the last twelve months (EPS of -$0.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alpha Teknova
Company profileAlpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Stephen Gunstream
- Headquarters
- Hollister, CA
- Employees
- 158
- IPO year
- 2021
- Website
- teknova.com
Financial highlights
Full financialsIn fiscal 2025, Alpha Teknova generated $40.5 million in revenue, up 7.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Alpha Teknova reported a net loss of $17.3 million, compared with a loss of $26.7 million a year earlier. Gross margin was 33.2% (up from 19.2%) and operating margin -41.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $40.52M | $37.74M | $36.68M | $41.42M | $36.89M |
| Growth | +7.35% | +2.89% | -11.43% | +12.27% | +17.88% |
| Net income | $-17.26M | $-26.75M | $-36.78M | $-47.47M | $-9.80M |
| EPS (diluted) | $-0.32 | $-0.57 | $-1.16 | $-1.69 | $-0.61 |
Analyst forecast
ForecastConsensus (8 analysts)
none
Avg. price target
$9.83+28.83%
- Strong buy 0
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.08 vs $-0.06
- Surprise
- -33.33%
TKNO news
All TKNO news- Alpha Teknova, Inc. Reports Third Quarter 2026 Revenue of $12.7 million and Raises Revenue Guidance to $46-48 millionNasdaqTKNO, UHAL.B
- Teknova Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Alpha Teknova Consensus Price Target Raised by 19.05% to $10.93NasdaqTKNO, BF.A
- Alpha Teknova, Inc. Enters Underwriting Agreement for 8,000,000 Share Public Offering and Announces Preliminary Financial Estimates for the Three Months Ended September 30, 2026NasdaqTKNO, LEN.B
- Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire
- Teknova Prices $40 Mln Public Offering At $5 Per ShareNasdaqTKNO, HEI.A
- Teknova Announces Preliminary Q3 Estimates, Launches Proposed Stock Offering; Stock Down 21%NasdaqTKNO, HEI.A
- Teknova Announces Pricing of $40 Million Public Offering of Common StockGlobeNewswire
Alpha Teknova peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs TKNO |
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs TKNO |
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs TKNO |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs TKNO |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs TKNO |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs TKNO |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs TKNO |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs TKNO |
Indexes, lists and sector
Alpha Teknova stock FAQ
What is Alpha Teknova's stock price today?
TKNO last traded at $7.63 as of Nov 20, 4:00 PM EST, down 2.30% on the day. Prices are delayed at least 15 minutes.
Who is Alpha Teknova's CEO?
Mr. Stephen Gunstream is the chief executive officer of Alpha Teknova Inc., which has about 158 employees.
What is the TKNO 52-week high?
The 52-week high for TKNO is $9.48 and the 52-week low is $1.91. The stock is currently 19.5% below its high.